Free shipping on all orders over $ 500

CC214-2 

Cat. No. M27987

All AbMole products are for research use only, cannot be used for human consumption.

CC214-2  Structure

Price and Availability

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.

Quality Control & Documentation
Biological Activity

CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin-resistant signaling and the growth of glioblastomas in vitro and in vivo.

Chemical Information
Molecular Weight 383.44
Formula C20H25N5O3
CAS Number 1228012-18-7
Form Solid
Solubility (25°C) DMSO 12.5 mg/mL (ultrasonic and warming and heat to 60°C)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Rokeya Tasneen, et al. Antimicrob Agents Chemother. Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

[2] Wei Wei, et al. Cancer Cell. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

[3] Ma Carmen Herrero-Sánchez, et al. Br J Haematol. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control

[4] Beatrice Gini, et al. Clin Cancer Res. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas

[5] Deborah S Mortensen, et al. Bioorg Med Chem Lett. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase

Related mTOR Products
AZD8055

AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase (both complexes mTORC1 and mTORC2) with an IC50 of 0.8 nM.
Deforolimus

Deforolimus (also known as AP23573 and MK-8669) is an investigational targeted and small-molecule mTOR inhibitor. *The compound is unstable in solutions, freshly prepared is recommended

Everolimus

Everolimus (RAD001) also known as SDZ-RAD and Certican is an mTOR inhibitor with IC50 of 0.63 nM.
KU-0063794

KU-0063794 is a potent and selective mTOR inhibitor with IC50 values of approximately 10 nM for mTORC1 and mTORC2.
WYE-354

WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).
  Catalog
Abmole Inhibitor Catalog




Keywords: CC214-2  supplier, mTOR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.